Annual CFO
-$391.24 M
-$24.48 M-6.67%
December 31, 2024
Summary
- As of March 7, 2025, IBRX annual cash flow from operations is -$391.24 million, with the most recent change of -$24.48 million (-6.67%) on December 31, 2024.
- During the last 3 years, IBRX annual CFO has fallen by -$116.82 million (-42.57%).
- IBRX annual CFO is now -157.21% below its all-time high of -$152.11 million, reached on December 31, 2019.
Performance
IBRX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$85.13 M
+$13.63 M+13.81%
December 31, 2024
Summary
- As of March 7, 2025, IBRX quarterly cash flow from operations is -$85.13 million, with the most recent change of +$13.63 million (+13.81%) on December 31, 2024.
- Over the past year, IBRX quarterly CFO has increased by +$13.63 million (+13.81%).
- IBRX quarterly CFO is now -173.66% below its all-time high of -$31.11 million, reached on March 31, 2020.
Performance
IBRX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$391.22 M
+$30.14 M+7.15%
December 31, 2024
Summary
- As of March 7, 2025, IBRX TTM cash flow from operations is -$391.22 million, with the most recent change of +$30.14 million (+7.15%) on December 31, 2024.
- Over the past year, IBRX TTM CFO has increased by +$30.14 million (+7.15%).
- IBRX TTM CFO is now -1157.66% below its all-time high of -$31.11 million, reached on March 31, 2020.
Performance
IBRX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
IBRX Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -6.7% | +13.8% | +7.2% |
| 3 y3 years | -42.6% | +13.8% | +7.2% |
| 5 y5 years | -157.2% | +13.8% | +7.2% |
IBRX Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -42.6% | at low | -18.8% | +26.1% | -42.6% | +7.2% |
| 5 y | 5-year | -157.2% | at low | -173.7% | +26.1% | -1157.7% | +7.2% |
| alltime | all time | -157.2% | at low | -173.7% | +26.1% | -1157.7% | +7.2% |
ImmunityBio Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$391.24 M(+6.7%) | -$85.13 M(-13.8%) | -$391.22 M(-7.2%) |
| Sep 2024 | - | -$98.76 M(-1.6%) | -$421.36 M(+2.8%) |
| Jun 2024 | - | -$100.35 M(-6.2%) | -$410.00 M(+5.3%) |
| Mar 2024 | - | -$106.98 M(-7.2%) | -$389.43 M(+6.2%) |
| Dec 2023 | -$366.76 M(+8.7%) | -$115.27 M(+31.9%) | -$366.76 M(+7.2%) |
| Sep 2023 | - | -$87.40 M(+9.6%) | -$342.21 M(+2.0%) |
| Jun 2023 | - | -$79.77 M(-5.4%) | -$335.41 M(-3.3%) |
| Mar 2023 | - | -$84.31 M(-7.1%) | -$346.89 M(+2.8%) |
| Dec 2022 | -$337.51 M | -$90.73 M(+12.6%) | -$337.51 M(+6.0%) |
| Sep 2022 | - | -$80.60 M(-11.7%) | -$318.42 M(+2.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2022 | - | -$91.25 M(+21.8%) | -$310.54 M(+7.5%) |
| Mar 2022 | - | -$74.93 M(+4.6%) | -$288.88 M(+5.3%) |
| Dec 2021 | -$274.42 M(+59.8%) | -$71.64 M(-1.5%) | -$274.42 M(+5.4%) |
| Sep 2021 | - | -$72.72 M(+4.5%) | -$260.38 M(+15.9%) |
| Jun 2021 | - | -$69.59 M(+15.1%) | -$224.66 M(+11.7%) |
| Mar 2021 | - | -$60.47 M(+5.0%) | -$201.09 M(+17.1%) |
| Dec 2020 | -$171.72 M(+12.9%) | -$57.60 M(+55.7%) | -$171.72 M(+50.5%) |
| Sep 2020 | - | -$36.99 M(-19.6%) | -$114.12 M(+48.0%) |
| Jun 2020 | - | -$46.02 M(+47.9%) | -$77.13 M(+147.9%) |
| Mar 2020 | - | -$31.11 M | -$31.11 M |
| Dec 2019 | -$152.11 M | - | - |
FAQ
- What is ImmunityBio annual cash flow from operations?
- What is the all time high annual CFO for ImmunityBio?
- What is ImmunityBio annual CFO year-on-year change?
- What is ImmunityBio quarterly cash flow from operations?
- What is the all time high quarterly CFO for ImmunityBio?
- What is ImmunityBio quarterly CFO year-on-year change?
- What is ImmunityBio TTM cash flow from operations?
- What is the all time high TTM CFO for ImmunityBio?
- What is ImmunityBio TTM CFO year-on-year change?
What is ImmunityBio annual cash flow from operations?
The current annual CFO of IBRX is -$391.24 M
What is the all time high annual CFO for ImmunityBio?
ImmunityBio all-time high annual cash flow from operations is -$152.11 M
What is ImmunityBio annual CFO year-on-year change?
Over the past year, IBRX annual cash flow from operations has changed by -$24.48 M (-6.67%)
What is ImmunityBio quarterly cash flow from operations?
The current quarterly CFO of IBRX is -$85.13 M
What is the all time high quarterly CFO for ImmunityBio?
ImmunityBio all-time high quarterly cash flow from operations is -$31.11 M
What is ImmunityBio quarterly CFO year-on-year change?
Over the past year, IBRX quarterly cash flow from operations has changed by +$13.63 M (+13.81%)
What is ImmunityBio TTM cash flow from operations?
The current TTM CFO of IBRX is -$391.22 M
What is the all time high TTM CFO for ImmunityBio?
ImmunityBio all-time high TTM cash flow from operations is -$31.11 M
What is ImmunityBio TTM CFO year-on-year change?
Over the past year, IBRX TTM cash flow from operations has changed by +$30.14 M (+7.15%)